- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00277810
Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease
July 1, 2020 updated by: Pfizer
A 6-Month, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Safety, Tolerability, and Efficacy Study of 3 Doses of Lecozotan (SRA-333) SR in Outpatients With Mild to Moderate Alzheimer's Disease Treated With a Cholinesterase Inhibitor
The purpose of the study is to determine the safety, tolerability, and efficacy of 3 doses of lecozotan in combination with a cholinesterase inhibitor in patients with mild to moderate Alzheimer's disease (AD).
Study Overview
Study Type
Interventional
Enrollment (Actual)
250
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Av. Belgrano, Argentina, 2945
-
Buenos Aires, Argentina
-
Calle Adolfo Alsina, Argentina, 2184
-
Cervino, Argentina, 3356
-
Galvan, Argentina, 4102
-
Gascon, Argentina, 450
-
Larrea, Argentina, 1035
-
Nueva York, Argentina, 3952
-
Pilar, Argentina, 950
-
-
-
-
-
Adelaide, Australia, 5000
-
East Gosford, Australia, 2250
-
Hornsby, Australia, 2077
-
Randwick, Australia, 2031
-
Victoria, Australia, 3081
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T5G 0B7
-
Medicine Hat, Alberta, Canada, T1A 4C2
-
-
New Brunswick
-
Moncton, New Brunswick, Canada, E1C 4B7
-
-
Ontario
-
Ottawa, Ontario, Canada, K1N 5C8
-
-
Quebec
-
Montreal, Quebec, Canada, H4H 1R3
-
-
-
-
-
Helsinki, Finland, 00120
-
Joensuu, Finland, 80100
-
Kuopio, Finland, 70211
-
-
-
-
-
Bordeaux, France, 33076
-
Montpellier, France, 34295
-
Nice, France, 06002
-
Toulouse, France, 31300
-
-
-
-
-
Roma, Italy, 00168
-
Roma, Italy, 00143
-
-
-
-
-
Gdansk - Wrzeszcz, Poland, 00-282
-
Krakow, Poland, 31-530
-
Krakow, Poland, 30-393
-
Lodz, Poland, 92-216
-
Lublin, Poland, 20-022
-
Sopot, Poland, 81-824
-
Szczecin, Poland, 70-356
-
-
-
-
-
Bloemfontein, South Africa, 9301
-
Cape Town, South Africa, 7500
-
Johannesburg, South Africa, 2197
-
Somerset West, South Africa, 7130
-
-
-
-
-
Barcelona, Spain, 08036
-
Barcelona, Spain, 08003
-
Barcelona, Spain, 08025
-
Barcelona, Spain, 08014
-
Madrid, Spain, 28040
-
Madrid, Spain, 28046
-
-
-
-
-
Belfast, United Kingdom, BT9 7BL
-
Glasgow, United Kingdom, G20 0XA
-
Sheffield, United Kingdom, S35 8QS
-
Southampton, United Kingdom, SO30 3JB
-
Swindon, United Kingdom, SN1 4JU
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85013
-
Tucson, Arizona, United States, 85741
-
-
California
-
Costa Mesa, California, United States, 92626
-
Fresno, California, United States, 93720
-
La Jolla, California, United States, 92037
-
Orange, California, United States, 92868
-
-
Florida
-
Delray Beach, Florida, United States, 33445
-
Fort Lauderdale, Florida, United States, 33321
-
Fort Myers, Florida, United States, 33916
-
Hallandale Beach, Florida, United States, 33009
-
Hialeah, Florida, United States, 33016
-
Jacksonville, Florida, United States, 33216
-
Miami, Florida, United States, 33176
-
Miami Beach, Florida, United States, 33154
-
Orlando, Florida, United States, 32806
-
Sarasota, Florida, United States, 34239
-
South Miami, Florida, United States, 33143
-
Tampa, Florida, United States, 33617
-
West Palm Beach, Florida, United States, 33407
-
-
Missouri
-
Saint Louis, Missouri, United States, 63104
-
-
New Jersey
-
Long Branch, New Jersey, United States, 07740
-
Manchester Twp., New Jersey, United States, 08759
-
-
New York
-
Albany, New York, United States, 12208
-
Cedarhurst, New York, United States, 11516
-
Staten Island, New York, United States, 10312
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27103
-
-
Ohio
-
Columbus, Ohio, United States, 43210
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74104
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
-
-
Rhode Island
-
East Providence, Rhode Island, United States, 02914
-
-
Tennessee
-
Memphis, Tennessee, United States, 38119
-
-
Texas
-
Houston, Texas, United States, 77030
-
-
Vermont
-
Bennington, Vermont, United States, 05201
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of probable Alzheimer's disease
- Current use of cholinesterase inhibitor
- Able to give signed and dated informed consent and lives with appropriate caregiver at home or in community dwelling with caregiver accompanying patient to all visits and visiting patient at least daily for duration of the study
Exclusion Criteria:
- Significant neurological disease other than AD
- Diagnosis of major depression
- History of stroke or other heart disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A
|
one of 3 doses of lecozotan sr dose for 6 months as an extension to a 6 month study with patients required to be on a cholinesterase inhibitor 2, 5, or 10 mg of lecozotan sr
|
Experimental: B
|
one of 3 doses of lecozotan sr dose for 6 months as an extension to a 6 month study with patients required to be on a cholinesterase inhibitor 2, 5, or 10 mg of lecozotan sr
|
Experimental: C
|
one of 3 doses of lecozotan sr dose for 6 months as an extension to a 6 month study with patients required to be on a cholinesterase inhibitor 2, 5, or 10 mg of lecozotan sr
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
All events and physical and neurological function and score change from baseline to 24 weeks in ratings for cognitive and global function scales
Time Frame: 6 mo extension study: week 24
|
6 mo extension study: week 24
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Score change from baseline to 24 weeks on functional and behavioral scales
Time Frame: week 24
|
week 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2006
Primary Completion (Actual)
June 1, 2008
Study Completion (Actual)
June 1, 2008
Study Registration Dates
First Submitted
January 12, 2006
First Submitted That Met QC Criteria
January 12, 2006
First Posted (Estimate)
January 16, 2006
Study Record Updates
Last Update Posted (Actual)
July 7, 2020
Last Update Submitted That Met QC Criteria
July 1, 2020
Last Verified
July 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3098B1-203, 3098B1-204
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on lecozotan SR (SRA-333)
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedAlzheimer's DiseaseUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedAlzheimer DiseaseGermany
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedAlzheimer DiseaseFrance
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedAlzheimer DiseaseUnited States, Canada, South Africa, Argentina, Australia
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted